𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

✍ Scribed by Marin, D; Marktel, S; Bua, M; Szydlo, R M; Franceschino, A; Nathan, I; Foot, N; Crawley, C; Na Nakorn, T; Olavarria, E

Book ID
110055531
Publisher
Nature Publishing Group
Year
2003
Tongue
English
Weight
123 KB
Volume
17
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 1 study of tipifarnib in combinati
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
✍ Jorge Cortes; Alfonso QuintΓ‘s-Cardama; Guillermo Garcia-Manero; Susan O'Brien; D πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. ## METHODS. Tw

Dynamics and management of cytopenias as
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
✍ Alfonso QuintΓ‘s-Cardama; Fabio Pires De Souza Santos; Hagop Kantarjian; Susan O' πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 160 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure. ## METHODS: Data were analyzed from 130 patients with CP CML who were trea